rss
Br J Ophthalmol 87:327-329 doi:10.1136/bjo.87.3.327
  • Original Article
    • Clinical science

Neoadjuvant chemotherapy for extensive unilateral retinoblastoma

Table 1

Clinical summary of the patients

Patients (age) Clinicoradiological features Neoadjuvant treatment Evaluation Enucleation histology Postoperative treatment Post-treatment response
*Etoposide 100 mg/m2/day, D1–D5, carboplatin 160 mg/m2/day, D1–D5.2
CADO: cyclophosphamide 300 mg/m2/day, D1–D5, vincristine 1.5 mg/m2/day, D1, D5, adriamycin 30 mg/m2/day, D4, D5).9
‡Vincristine 1.5 mg/m2/day, D1, D5 cyclophosphamide 1 g/m2/day, D1–D3.9,10
§Etoposide 150 mg/m2/day, D1–D3, cyclophosphamide 1 g/m2/day, D1–D3.8
¶CARBOPEC carboplatin 350 mg/m2/day, D1–D5, etoposide 350 mg/m2/day, D1–D5, cyclophosphamide 1.6 g/m2/day, D2–D5.11
1 (3.5 years) Buphthalmia 1 etoposide-carboplatin Clinical: regression Necrotic tumour Invasion: prelaminar, choroidal, ciliary bodies 2 etoposide-carboplatin* 2 cado† 21 months Cr
2 (22 months) Buphthalmia 1 etoposide-carboplatin Clinical: regression Necrotic tumour Invasion: intralaminar 1 etoposide-carboplatin 2 vincristine-endoxan‡ 15 months Cr
3 (22 months) Orbital portion of optic nerve 3 etoposide-carboplatin CT/MRI: tumour reduction CSF (−) Necrotic tumour No residual optic nerve invasion 2 etoposide-cyclophosphamide§ CARBOPEC¶ 40 months Cr
4 (1 year) Orbital portion of optic nerve 3 etoposide-carboplatin 1 etoposide-cyclophosphamide CT/MRI: tumour reduction CSF (−) Necrotic tumour Invasion: prelaminar 3 etoposide-carboplatin 1 etoposide-cyclophosphamide CARBOPEC 36 months Cr
5 (8 years) Prechiasmatic portion of optic nerve 2 etoposide-carboplatin Intrathecal thiotepa MRI: tumour reduction CSF (−) Macroscopic invasion of optic nerve resection margins Necrotic tumour 3 etoposide-cyclophosphamide 1 etoposide-arboplatin CARBOPEC Radiotherapy 12 months CR
6 (18 months) Buphthalmia Prechiasmatic portion of optic nerve 2 etoposide-carboplatin CT: tumour reduction CSF (+) No enucleation Early meningeal progression Died

This Article

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.